Another study has demonstrated that pristimerin improves intracellular ROS levels through both stimulating excessive generation of superoxide in mitochondria and abrogating intracellular ROS scavenger GSH level in glioma cells, consequently activates JNK (54). Here, MAPK8 is linked to central nervous system cancer.